BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/26/2023 8:16:12 AM | Browse: 363 | Download: 1061
 |
Received |
|
2022-12-27 08:24 |
|
Peer-Review Started |
|
2022-12-27 08:25 |
|
First Decision by Editorial Office Director |
|
2023-01-06 17:47 |
|
Return for Revision |
|
2023-01-06 17:47 |
|
Revised |
|
2023-01-30 08:02 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-03-17 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-03-20 23:13 |
|
Articles in Press |
|
2023-03-20 23:13 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-04-18 04:17 |
|
Publish the Manuscript Online |
|
2023-04-26 08:16 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Human pluripotent stem cell-derived β cells: Truly immature islet β cells for type 1 diabetes therapy?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Helen Jiang and Fang-Xu Jiang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Juvenile Diabetes Research Foundation |
4-2006-1025 |
| Diabetes Australia Research Trust |
|
| Telethon Perth Children’s Hospital Research Fund (TPCHRF) |
|
|
| Corresponding Author |
Fang-Xu Jiang, PhD, Adjunct Associate Professor, School of Biomedical Sciences, University of Western Australia, 35 Stirling Hwy, Crawley WA 6009, Perth 6009, Australia. fang-xu.jiang@perkins.uwa.edu.au |
| Key Words |
Human pluripotent stem cells; Stem cell-derived β cells; Islet β cells; Type 1 diabetes mellitus; Cell replacement therapy |
| Core Tip |
Diabetes mellitus (DM) is a metabolic condition of absolute or relative deficiency in insulin. Since the discovery of insulin 100 years ago, there has been slow progress in the treatment of type 1 DM (T1DM) in clinical practice. In the scientific community however, there is much interest and progression in the research of human pluripotent stem cell derived insulin producing β-like cells, pervasively known as stem cell-derived β cells (SC-β cells). If they are determined to be genuine, scalable and functionally matured, SC-β cells have the potential to cure T1DM through cell replacement therapy. |
| Publish Date |
2023-04-26 08:16 |
| Citation |
Jiang H, Jiang FX. Human pluripotent stem cell-derived β cells: Truly immature islet β cells for type 1 diabetes therapy? World J Stem Cells 2023; 15(4): 182-195 |
| URL |
https://www.wjgnet.com/1948-0210/full/v15/i4/182.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v15.i4.182 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
